Linked Life Data

6138009

Source:http://linkedlifedata.com/resource/pubmed/id/6138009

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1983-11-23
pubmed:abstractText
Buspirone hydrochloride, a compound with novel chemical structure, has been reported to be anxiolytic in man. Its mechanism of action as an anxiolytic is unknown, but preclinical studies have shown that it produces effects consistent with both a dopamine agonist and antagonist. In man, buspirone hydrochloride at doses of 30, 60, and 90 mg orally significantly elevated plasma prolactin (PRL) and growth hormone (GH) concentrations. The apparent increase in PRL secretion was dose dependent, but that of GH was not. The increase in PRL secretion could be due to a dopamine antagonist effect at the pituitary gland. A dopamine agonist action at hypothalamic dopamine receptors could account for the increase in GH secretion. Benzodiazepine anxiolytic drugs also increase serum GH levels in man, by a mechanism that has not been clearly established. It may be that buspirone and benzodiazepine drugs stimulate GH secretion by a common mechanism that is related to their anxiolytic actions.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0003-990X
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1099-102
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
The effect of buspirone on prolactin and growth hormone secretion in man.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't